星空体育官方入口网站网址大全-登录入口官网

#BCL2#

17篇内容 | 969人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1446601, encodeId=800a144660117, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, objectType=article, longId=739079, objectId=dbbfe390796d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbbfe390796d, replyNumber=0, likeNumber=82, createdTime=2022-09-13, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbbfe390796d, moduleTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dbbfe390796d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446600, encodeId=1dca14466001e, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=BLOOD ：通过与蛋白质翻译抑制剂和bcl2共同治疗具有RUNX1突变的AML的有效治疗, objectType=article, longId=218152, objectId=7266218152a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7266218152a9, replyNumber=0, likeNumber=70, createdTime=2021-10-07, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7266218152a9, moduleTitle=BLOOD ：通过与蛋白质翻译抑制剂和bcl2共同治疗具有RUNX1突变的AML的有效治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7266218152a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446599, encodeId=b2271446599c3, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Neuroscience：BCL2的相互作用蛋白Protein-3-like/NIX介导的线粒体自噬在年龄相关听力损失过程中发挥重要作用 , objectType=article, longId=205103, objectId=3c65205103e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c65205103e1, replyNumber=0, likeNumber=62, createdTime=2021-01-02, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c65205103e1, moduleTitle=Neuroscience：BCL2的相互作用蛋白Protein-3-like/NIX介导的线粒体自噬在年龄相关听力损失过程中发挥重要作用 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3c65205103e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446598, encodeId=a49f144659871, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Cell Death Differ：单细胞成像研究显示BCL(X)L和BCL2增加乳腺癌细胞的代谢适应性, objectType=article, longId=204956, objectId=9c9820495645, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c9820495645, replyNumber=0, likeNumber=42, createdTime=2020-12-30, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c9820495645, moduleTitle=Cell Death Differ：单细胞成像研究显示BCL(X)L和BCL2增加乳腺癌细胞的代谢适应性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9c9820495645)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446597, encodeId=c9db144659e8a, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制, objectType=article, longId=203317, objectId=5a9020331ec1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a9020331ec1, replyNumber=0, likeNumber=50, createdTime=2020-11-14, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a9020331ec1, moduleTitle=Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5a9020331ec1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446596, encodeId=10b4144659638, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Blood：肿瘤靶向纳米颗粒可改善BCL2和MCL1双重抑制的治疗效果, objectType=article, longId=202288, objectId=af35202288ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af35202288ff, replyNumber=0, likeNumber=70, createdTime=2020-10-21, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af35202288ff, moduleTitle=Blood：肿瘤靶向纳米颗粒可改善BCL2和MCL1双重抑制的治疗效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=af35202288ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446595, encodeId=704a144659551, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Blood：携带MYC和BCL2/BCL6重排的高级别B细胞淋巴瘤, objectType=article, longId=179636, objectId=788e1e96369b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=788e1e96369b, replyNumber=0, likeNumber=68, createdTime=2019-09-19, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=788e1e96369b, moduleTitle=Blood：携带MYC和BCL2/BCL6重排的高级别B细胞淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=788e1e96369b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446594, encodeId=82f5144659400, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Blood：联合抑制Bcl2和NFκB可协同诱导CTCL细胞死亡、限制其肿瘤生长, objectType=article, longId=167794, objectId=281716e79481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=281716e79481, replyNumber=0, likeNumber=52, createdTime=2019-06-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=281716e79481, moduleTitle=Blood：联合抑制Bcl2和NFκB可协同诱导CTCL细胞死亡、限制其肿瘤生长, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=281716e79481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446593, encodeId=aa8b144659339, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%, objectType=article, longId=164498, objectId=282016449820, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282016449820, replyNumber=0, likeNumber=53, createdTime=2019-04-19, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282016449820, moduleTitle=新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=282016449820)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446592, encodeId=f8fe1446592c3, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Cell Death Dis：GIT1通过在饥饿条件下破坏Beclin1和Bcl2的结合而促成破骨细胞的自噬 GIT1 tōng, objectType=article, longId=156470, objectId=c3dc1564e096, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3dc1564e096, replyNumber=0, likeNumber=60, createdTime=2018-12-24, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3dc1564e096, moduleTitle=Cell Death Dis：GIT1通过在饥饿条件下破坏Beclin1和Bcl2的结合而促成破骨细胞的自噬 GIT1 tōng, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c3dc1564e096)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446591, encodeId=79df14465911b, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Blood：BH3-mimetic工具指导BCL2 BH3-mimetics和MCL1 BH3-mimetics分开用于治疗骨髓瘤, objectType=article, longId=150925, objectId=d786150925d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d786150925d7, replyNumber=0, likeNumber=41, createdTime=2018-10-14, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d786150925d7, moduleTitle=Blood：BH3-mimetic工具指导BCL2 BH3-mimetics和MCL1 BH3-mimetics分开用于治疗骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d786150925d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446590, encodeId=181e14465902d, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Signal Transduct Target Ther：靶向MUC1-C可抑制三阴性乳腺癌中的BCL2A1, objectType=article, longId=138429, objectId=e601138429e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e601138429e0, replyNumber=0, likeNumber=49, createdTime=2018-05-19, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e601138429e0, moduleTitle=Signal Transduct Target Ther：靶向MUC1-C可抑制三阴性乳腺癌中的BCL2A1, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e601138429e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446589, encodeId=86281446589aa, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果, objectType=article, longId=120735, objectId=9988120e352a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9988120e352a, replyNumber=0, likeNumber=56, createdTime=2017-11-21, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9988120e352a, moduleTitle=ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9988120e352a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446588, encodeId=36dc1446588d7, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Blood：JAK1/2抑制剂与BCL2抑制剂联用或能打破骨髓微环境的保护作用, objectType=article, longId=102563, objectId=be2010256397, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be2010256397, replyNumber=0, likeNumber=54, createdTime=2017-06-21, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be2010256397, moduleTitle=Blood：JAK1/2抑制剂与BCL2抑制剂联用或能打破骨髓微环境的保护作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=be2010256397)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446587, encodeId=0cea144658e90, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Am J Hematol：BCL2突变是否导致利妥昔单抗治疗的滤泡性淋巴瘤患者预后不良？, objectType=article, longId=100766, objectId=a2e7100e6654, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e7100e6654, replyNumber=0, likeNumber=57, createdTime=2017-06-07, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e7100e6654, moduleTitle=Am J Hematol：BCL2突变是否导致利妥昔单抗治疗的滤泡性淋巴瘤患者预后不良？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a2e7100e6654)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446586, encodeId=236014465866c, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=Prog Retin Eye Res：BCL2基因家族如何调控视网膜神经节细胞的死亡过程, objectType=article, longId=92389, objectId=662692389e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=662692389e0, replyNumber=0, likeNumber=59, createdTime=2017-03-20, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=662692389e0, moduleTitle=Prog Retin Eye Res：BCL2基因家族如何调控视网膜神经节细胞的死亡过程, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=662692389e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1446585, encodeId=0f321446585f3, content=<a href='/topic/show?id=1f8a326e6f' target=_blank style='color:#2F92EE;'>#BCL2#</a>, objectTitle=JCO：MYC和BCL2蛋白高表达可预测弥漫性大B细胞淋巴瘤患者预后, objectType=article, longId=7374, objectId=d039e37452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d039e37452, replyNumber=0, likeNumber=41, createdTime=2012-06-27, rootId=0, userName=Boyinsh, userId=fdbf5248081, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d039e37452, moduleTitle=JCO：MYC和BCL2蛋白高表达可预测弥漫性大B细胞淋巴瘤患者预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d039e37452)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BCL2

2020-05-29

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）

2022-09-13

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

BLOOD ：通过与蛋白质翻译抑制剂和bcl2共同治疗具有RUNX1突变的AML的有效治疗

2021-10-07

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Neuroscience：BCL2的相互作用蛋白Protein-3-like/NIX介导的线粒体自噬在年龄相关听力损失过程中发挥重要作用

2021-01-02

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Cell Death Differ：单细胞成像研究显示BCL(X)L和BCL2增加乳腺癌细胞的代谢适应性

2020-12-30

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制

2020-11-14

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Blood：肿瘤靶向纳米颗粒可改善BCL2和MCL1双重抑制的治疗效果

2020-10-21

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Blood：携带MYC和BCL2/BCL6重排的高级别B细胞淋巴瘤

2019-09-19

智智灵药 (审核中...)

前往app查看评论内容

#BCL2#

Blood：联合抑制Bcl2和NFκB可协同诱导CTCL细胞死亡、限制其肿瘤生长

2019-06-08

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%

2019-04-19

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Cell Death Dis：GIT1通过在饥饿条件下破坏Beclin1和Bcl2的结合而促成破骨细胞的自噬 GIT1 tōng

2018-12-24

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Blood：BH3-mimetic工具指导BCL2 BH3-mimetics和MCL1 BH3-mimetics分开用于治疗骨髓瘤

2018-10-14

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Signal Transduct Target Ther：靶向MUC1-C可抑制三阴性乳腺癌中的BCL2A1

2018-05-19

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果

2017-11-21

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Blood：JAK1/2抑制剂与BCL2抑制剂联用或能打破骨髓微环境的保护作用

2017-06-21

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Am J Hematol：BCL2突变是否导致利妥昔单抗治疗的滤泡性淋巴瘤患者预后不良？

2017-06-07

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

Prog Retin Eye Res：BCL2基因家族如何调控视网膜神经节细胞的死亡过程

2017-03-20

Boyinsh (审核中...)

前往app查看评论内容

#BCL2#

JCO：MYC和BCL2蛋白高表达可预测弥漫性大B细胞淋巴瘤患者预后

2012-06-27

科室
- - 订阅+
  - 更多科室
工具
服务